• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·France·Healthcare·ALMDT.PA
Share

Median Technologies SA Stocks

€ 4.24Last Updated 21.10.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

€ 226.97M

€ 4.24
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.10.2026 15:25

Morning in New York: Tech Giants Wake Up the "Bears"

22.10.2026 15:05

Hermès has been hit by a decline in demand in China. What should investors do with their shares after a 40% drop?

22.10.2026 14:48

Brent surged to its highest level since May. The NYT reported that the U.S. is preparing strikes against Iran

22.10.2026 14:02

eBay shares rose following the announcement of a 9% workforce reduction. Should you buy these stocks?

22.10.2026 13:20

The Euro vs. the Barricades: What Affects Its Exchange Rate More Than the Crisis in France

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026